RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma

Epigenetics

Volumn 8, Issue 9, 2013, Pages 893-898

  Gharanei, Seley ^a   Brini, Anna T ^b,c   Vaiyapuri, Sumathi ^a   Alholle, Abdullah ^a   Dallol, Ashraf ^d   Arrigoni, Elena ^b   Kishida, Takeshi ^e   Hiruma, Toru ^e   Avigad, Smadar ^f   Grimer, Robert ^a   Maher, Eamonn R ^a   Latif, Farida ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e KANAGAWA CANCER CENTER   (Japan)

^f SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Ewing sarcoma; Methylation; RASSF1A; RASSF2; Survival

Indexed keywords

5 AZA 2' DEOXYCYTIDINE;

ADOLESCENT; ADULT; AGE; ARTICLE; BONE MARROW BIOPSY; CANCER PROGNOSIS; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; EWING SARCOMA; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NORMAL HUMAN; NUCLEAR LOCALIZATION SIGNAL; OVERALL SURVIVAL; RASSF1A GENE; RASSF2 GENE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING;

EWING SARCOMA; METHYLATION; RASSF1A; RASSF2; SURVIVAL;

ADOLESCENT; AZACITIDINE; CELL LINE, TUMOR; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; SARCOMA, EWING; TUMOR SUPPRESSOR PROTEINS;

EID: 84883498462     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.25617     Document Type: Article

References (22)

1. Lessnick SL, Ladanyi M. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol 2012; 7:145-59; PMID:21942527; http://dx.doi.org/10.1146/annurevpathol-011110-130237
2. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25:315-9; PMID:10888881; http://dx.doi.org/10.1038/77083
3. Dallol A, Hesson LB, Matallanas D, Cooper WN, O'Neill E, Maher ER, et al. RAN GTPase is a RASSF1A effector involved in controlling microtubule organization. Curr Biol 2009; 19:1227-32; PMID:19559616; http://dx.doi.org/10.1016/j.cub.2009.05.064
4. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009; 1796:114-28; PMID:19344752
5. Underhill-Day N, Hill V, Latif F. N-terminal RASSF family: RASSF7-RASSF10. Epigenetics 2011; 6:284-92; PMID:21116130; http://dx.doi.org/10.4161/ epi.6.3.14108
6. Avigad S, Shukla S, Naumov I, Cohen IJ, Ash S, Meller I, et al. Aberrant methylation and reduced expression of RASSF1A in Ewing sarcoma. Pediatr Blood Cancer 2009; 53:1023-8; PMID:19637319; http://dx.doi. org/10.1002/pbc.22115
7. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19:491-505; PMID:20951342; http://dx.doi.org/10.1016/j.devcel. 2010.09.011
8. Cooper WN, Dickinson RE, Dallol A, Grigorieva EV, Pavlova TV, Hesson LB, et al. Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene 2008; 27:1805-11; PMID:17891178; http://dx.doi.org/10.1038/ sj.onc.1210805
9. Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Ishizuka T, Saito R, et al. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers. Int J Oncol 2007; 31:169-73; PMID:17549418
10. Luo D, Ye T, Li TQ, Tang P, Min SD, Zhao GF, et al. Ectopic expression of RASSF2 and its prognostic role for gastric adenocarcinoma patients. Exp Ther Med 2012; 3:391-6; PMID:22969901
11. Schagdarsurengin U, Richter AM, Hornung J, Lange C, Steinmann K, Dammann RH. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer 2010; 9:264; PMID:20920251; http://dx.doi.org/10.1186/1476-4598-9-264
12. Imai T, Toyota M, Suzuki H, Akino K, Ogi K, Sogabe Y, et al. Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. Cancer Sci 2008; 99:958-66; PMID:18294275; http://dx.doi.org/10.1111/j.1349-7006.2008.00769.x
13. Nagasaka T, Tanaka N, Cullings HM, Sun DS, Sasamoto H, Uchida T, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst 2009; 101:1244-58; PMID:19700653; http://dx.doi.org/10.1093/jnci/djp265
14. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 2003; 278:28045-51; PMID:12732644; http://dx.doi. org/10.1074/jbc.M300554200
15. Clark J, Freeman J, Donninger H. Loss of RASSF2 Enhances Tumorigencity of Lung Cancer Cells and Confers Resistance to Chemotherapy. Mol Biol Int 2012; 2012:705948; PMID:22693671; http://dx.doi. org/10.1155/2012/705948
16. Cooper WN, Hesson LB, Matallanas D, Dallol A, von Kriegsheim A, Ward R, et al. RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene 2009; 28:2988-98; PMID:19525978; http://dx.doi.org/10.1038/onc.2009.152
17. Donninger H, Hesson L, Vos M, Beebe K, Gordon L, Sidransky D, et al. The Ras effector RASSF2 controls the PAR-4 tumor suppressor. Mol Cell Biol 2010; 30:2608-20; PMID:20368356; http://dx.doi. org/10.1128/MCB.00208-09
18. Song H, Kim H, Lee K, Lee DH, Kim TS, Song JY, et al. Ablation of Rassf2 induces bone defects and subsequent haematopoietic anomalies in mice. EMBO J 2012; 31:1147-59; PMID:22227519; http://dx.doi. org/10.1038/emboj.2011.480
19. Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, et al. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 2009; 8:42; PMID:19570220; http://dx.doi.org/10.1186/1476-4598-8-42
20. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-7; PMID:10102814; http://dx.doi. org/10.1126/science.284.5411.143
21. Gharanei S, Zatyka M, Astuti D, Fenton J, Sik A, Nagy Z, et al. Vacuolar-type H+-ATPase V1A subunit is a molecular partner of Wolfram syndrome 1 (WFS1) protein, which regulates its expression and stability. Hum Mol Genet 2013; 22:203-17; PMID:23035048; http://dx.doi.org/10.1093/hmg/dds400
22. Dallol A, Al-Maghrabi J, Buhmeida A, Gari MA, Chaudhary AG, Schulten HJ, et al. Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2012; 21:2069-75; PMID:23010642; http://dx.doi.org/10.1158/1055-9965.EPI-12-0755